Position of SGLT2i in prediabetes: A systematic review of literature

被引:0
|
作者
Biswas, Kaushik [1 ]
Reddy, Vijaya Bhaskar [2 ]
Seshadri, Krishna [3 ]
Kapoor, Nitin [4 ]
Dharmalingam, Mala [5 ]
Anthuvan, Thamburaj [6 ]
机构
[1] Med Superspecialty Hosp, Dept Endocrinol, Kolkata 700099, W Bengal, India
[2] Vijay Diabet, Dept Diabet & Endocrinol, Thyroid & Endocrine Clin, Pondicherry, India
[3] Chennai Diabet & Endocrinol Clin, Dept Endocrinol, Chennai, India
[4] Christian Med Coll & Hosp, Dept Endocrinol Diabet & Metab, Vellore, Tamil Nadu, India
[5] Bangalore Endocrinol & Diabet Res Ctr, Bangalore, Karnataka, India
[6] Savitribhai Phule Pune Univ, Dept Commerce & Management, Pune, Maharashtra, India
关键词
Cardiovascular complications; diabetes prevention; glycemic control; prediabetes; renal complications; SGLT2; inhibitors; CHRONIC KIDNEY-DISEASE; FOLLOW-UP; DIAGNOSIS; INDIA; EMPAGLIFLOZIN; ASSOCIATION; PREVALENCE; MANAGEMENT; PREDICTORS;
D O I
10.4103/jod.jod_238_24
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. (2002). Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616-1622. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, et al.; EMBRACE (2018). Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, etal.; ACMG Laboratory Quality Assurance Committee (2015). Standards and guidelines for the interpretation of sequence variants: ajoint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424. Sehouli J, Alfaro V, Gonz & aacute;lez-Martin A (2012). Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum- sensitive ovarian cancer: current evidence and future perspectives. Ann Oncol 23:556-562. Shao D, Cheng S, Guo F, Zhu C, Yuan Y, Hu K, et al. (2020). Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals. Cancer Sci 111:647-657. X, L, Kong B, J, R, H, (2017). multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian cancer patients. IntJ Gynecol Cancer 27:1650-1657. Wu Z, Zhang Q, Jin Y, Zhang X, Chen Y, Yang C, et al. (2024). Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area. BMC Cancer 24:411. Yousif HM, Mohammed RA, Missawi HM, Elsawaf ZM, Albasri AM (2019). Histopathological patterns of primary malignant ovarian neoplasms in different age groups in Almadinah Almunawwarah region, KSA. J Taibah Univ Med Sci 14:73-78. Zadabedini Masouleh T, Etchegary H, Hodgkinson K, Wilson BJ, Dawson L (2023). Beyond sterilization: a comprehensive review on the safety and efficacy of opportunistic salpingectomy as a preventative strategy for ovarian cancer. Curr Oncol 30:10152-10165. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. (2011). Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:353-357.
引用
收藏
页码:102 / 114
页数:13
相关论文
共 50 条
  • [41] Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D
    Gonzalez-Albarran, Olga
    Morales, Cristobal
    Perez-Maraver, Manuel
    Juan Aparicio-Sanchez, Jose
    Simo, Rafael
    DIABETES THERAPY, 2022, 13 (SUPPL 1) : 35 - 49
  • [42] Timing of SGLT2i initiation after acute myocardial infarction
    Dirk von Lewinski
    Ewald Kolesnik
    Faisal Aziz
    Martin Benedikt
    Norbert J. Tripolt
    Markus Wallner
    Peter N. Pferschy
    Friederike von Lewinski
    Nora Schwegel
    Rury R. Holman
    Abderrahim Oulhaj
    Deddo Moertl
    Jolanta Siller-Matula
    Harald Sourij
    Cardiovascular Diabetology, 22
  • [43] INDEPENDENT EFFECT OF SGLT2I ON DIASTOLIC FUNCTION IN HFREF POPULATION
    Stracqualursi, M.
    Nemola, G.
    Moscardelli, S.
    Santangelo, G.
    Buratti, S.
    Losito, M.
    Bursi, F.
    Guazzi, M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2024, 26
  • [44] Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
    Pradhan, Akshyaya
    Vohra, Shweta
    Vishwakarma, Pravesh
    Sethi, Rishi
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2019, 8 (06) : 1855 - 1862
  • [45] Safety and Efficacy of SGLT2i Post Orthotopic Heart Transplantation
    Sundaravel, S.
    Zolty, R.
    Stoller, D.
    Lowes, B.
    Lundgren, S.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S130 - S130
  • [46] SGLT2i Use in Pediatric Heart Failure: Multicenter Study
    Butts, R.
    Nandi, D.
    Hong, B.
    Lorts, A.
    Profita, E.
    Spinner, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S149 - S149
  • [47] Impact of SGLT2i Use on Functional Capacity in Heart Failure
    Jang, J.
    Nativi-Nicolau, J.
    Yip, D.
    Patel, P.
    Leoni-Moreno, J.
    Goswami, R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S333 - S333
  • [48] Characteristics of Inpatients with DKA and SGLT2i Use at a Tertiary Hospital
    Williamson, Shelley
    Taha, Mohamad B.
    Brown, Timothy R.
    Hebert, Sean
    Patel, Kershaw
    Narcisse, Victor J., III
    Sadhu, Archana R.
    DIABETES, 2022, 71
  • [49] SGLT2i After Kidney Transplantation: Ready for Prime Time?
    Francis, Ross Simon
    TRANSPLANTATION, 2022, 106 (09) : 1732 - 1733
  • [50] SGLT2i and loop diuretic withdrawal or downtitration in heart failure
    Domingo, Mar
    Ruiz-Cueto, Maria
    Teis, Albert
    Lupon, Josep
    Alonso, Nuria
    Bayes-Genis, Antoni
    REVISTA ESPANOLA DE CARDIOLOGIA, 2023, 76 (11): : 943 - 945